|
Volumn 72, Issue 25, 2018, Pages 3370-3372
|
Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CANAGLIFLOZIN;
DAPAGLIFLOZIN;
EMPAGLIFLOZIN;
ERTUGLIFLOZIN;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
ANTIDIABETIC AGENT;
ADULT;
AGE;
AGED;
CARDIOLOGIST;
CARDIOVASCULAR RISK;
CAUCASIAN;
DRUG LABELING;
ENDOCRINOLOGIST;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HIGH RISK PATIENT;
HUMAN;
LETTER;
MAJOR ADVERSE CARDIAC EVENT;
MAJOR CLINICAL STUDY;
MALE;
MASSACHUSETTS;
MEDICAL SPECIALIST;
MIDDLE AGED;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OUTPATIENT;
PATIENT SELECTION;
PRESCRIPTION;
PRIORITY JOURNAL;
RETROSPECTIVE STUDY;
RISK REDUCTION;
SEX RATIO;
TREATMENT OUTCOME;
UNITED STATES;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
LEGISLATION AND JURISPRUDENCE;
MULTICENTER STUDY;
TERTIARY CARE CENTER;
AGED;
CARDIOVASCULAR DISEASES;
DRUG LABELING;
DRUG PRESCRIPTIONS;
FEMALE;
HUMANS;
HYPOGLYCEMIC AGENTS;
MALE;
MIDDLE AGED;
RETROSPECTIVE STUDIES;
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;
TERTIARY CARE CENTERS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 85058874846
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2018.08.2202 Document Type: Letter |
Times cited : (101)
|
References (5)
|